{"id": "346485", "url": "https://fevir.net/resources/ResearchStudy/346485", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/study-registry-record"], "versionId": "10", "lastUpdated": "2026-01-26T16:43:36.479Z"}, "name": "CTIS_2024_516402_32_00_FHIR_Transform", "label": [{"type": {"coding": [{"code": "plain-language", "system": "http://terminology.hl7.org/CodeSystem/itle-type", "display": "Plain language title"}]}, "value": "Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU)"}, {"type": {"text": "Protocol code"}, "value": "APHP211039"}, {"type": {"coding": [{"code": "primary", "system": "http://terminology.hl7.org/CodeSystem/title-type", "display": "Primary title"}]}, "value": "Eculizumab dans le syndrome h\u00e9molytique et ur\u00e9mique associ\u00e9 \u00e0 l'urgence hypertensive: essai contr\u00f4l\u00e9 multicentrique randomis\u00e9 (HYPERSHU)", "language": "fr"}, {"type": {"coding": [{"code": "plain-language", "system": "http://terminology.hl7.org/CodeSystem/itle-type", "display": "Plain language title"}]}, "value": "Eculizumab dans le syndrome h\u00e9molytique et ur\u00e9mique associ\u00e9 \u00e0 l'urgence hypertensive: essai contr\u00f4l\u00e9 multicentrique randomis\u00e9 (HYPERSHU)", "language": "fr"}], "phase": {"text": "Therapeutic confirmatory (Phase III)", "coding": [{"code": "SEVCO:01035", "system": "https://fevir.net/sevco", "display": "phase 3 trial"}]}, "title": "Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU)", "citeAs": "Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU) [Database Entry: FHIR ResearchStudy Resource]. Contributors: Computable Publishing\u00ae: CTIS-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 346485. Revised 2026-01-26. Available at: https://fevir.net/resources/ResearchStudy/346485. Computable resource at: https://fevir.net/resources/ResearchStudy/346485#json.", "status": "active", "condition": [{"text": "Adult patients with aHUS associated with HE and severe kidney involvement (needing dialysis or serum creatinine \u2265 354\u03bcM)", "_text": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "Patients adultes pr\u00e9sentant un SHUA associ\u00e9 \u00e0 une HE et une atteinte r\u00e9nale s\u00e9v\u00e8re (n\u00e9cessitant une dialyse ou taux de cr\u00e9atinine s\u00e9rique \u2265  354\u00b5M)"}]}]}, "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-is-rare-disease", "valueBoolean": false}]}, {"coding": [{"code": "10079840", "system": "https://www.meddra.org", "display": "Atypical haemolytic uraemic syndrome", "version": "20.1"}]}], "contained": [{"id": "organization-554686", "name": "Assistance Publique Hopitaux De Paris", "description": "Hospital/Clinic/Other health care facility", "resourceType": "Organization"}, {"id": "contact-190857", "contact": [{"name": [{"text": "Dr El Karoui Khalil"}], "telecom": [{"value": "khalil.el-karoui@aphp.fr", "system": "email"}, {"value": "+33156016317", "system": "phone"}]}], "display": "Dr El Karoui Khalil khalil.el-karoui@aphp.fr", "organization": {"type": "Organization", "display": "Assistance Publique Hopitaux De Paris", "reference": "#organization-554686"}, "resourceType": "PractitionerRole"}, {"id": "contact-190858", "contact": [{"name": [{"text": "Dr El Karoui Khalil"}], "telecom": [{"value": "khalil.el-karoui@aphp.fr", "system": "email"}, {"value": "+33156016317", "system": "phone"}]}], "display": "Dr El Karoui Khalil khalil.el-karoui@aphp.fr", "organization": {"type": "Organization", "display": "Assistance Publique Hopitaux De Paris", "reference": "#organization-554686"}, "resourceType": "PractitionerRole"}], "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-is-low-intervention-trial", "valueBoolean": false}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail": {"name": "Computable Publishing\u00ae: CTIS-to-FEvIR Converter"}}], "objective": [{"name": "To demonstrate the efficacy of early Eculizumab administration added on standard of care BP control on dialysis-dependence at month 6 in HEaHUS patients with severely impaired initial renal function.", "type": {"coding": [{"code": "primary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Primary"}]}, "_name": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "D\u00e9montrer l'efficacit\u00e9 de l'administration pr\u00e9coce d'Eculizumab, ajout\u00e9e au contr\u00f4le standard de la pression art\u00e9rielle, sur la d\u00e9pendance \u00e0 la dialyse au troisi\u00e8me mois chez les patients atteints d\u2019SHUa-HE dont la fonction r\u00e9nale initiale est s\u00e9v\u00e8rement alt\u00e9r\u00e9e."}]}]}}, {"name": "To evaluate the role of complement biomarkers in predicting therapeutic response", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "_name": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "\u00c9valuer le r\u00f4le des biomarqueurs du compl\u00e9ment dans la pr\u00e9diction de la r\u00e9ponse th\u00e9rapeutique"}]}]}}, {"name": "To evaluate the frequency of complement genetic rare variants in this population", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "_name": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "\u00c9valuer la fr\u00e9quence des variants g\u00e9n\u00e9tiques rares du compl\u00e9ment dans cette population"}]}]}}, {"name": "To evaluate the efficacy of early eculizumab administration added on standard of care BP control on 3-month (W13) and 12 months renal replacement therapy risk", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "_name": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "\u00c9valuer l'efficacit\u00e9 de l'administration pr\u00e9coce d'\u00e9culizumab, ajout\u00e9e au contr\u00f4le de la pression art\u00e9rielle standard, sur le risque de traitement de suppl\u00e9ance r\u00e9nale \u00e0 3 mois et 12 mois"}]}]}}, {"name": "To evaluate the frequency of severe infections in both groups", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "_name": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "\u00c9valuer la fr\u00e9quence des infections graves dans les deux groupes"}]}]}}, {"name": "To evaluate the time to resolution of hemolysis and acute dialysis", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "_name": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "\u00c9valuer le temps de r\u00e9solution de l'h\u00e9molyse et de la dialyse aigu\u00eb"}]}]}}, {"name": "To evaluate the frequency of histological lesions and their prognosis (if kidney biopsy is performed)", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "_name": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "\u00c9valuer la fr\u00e9quence des l\u00e9sions histologiques et leur pronostic (si une biopsie r\u00e9nale est r\u00e9alis\u00e9e)"}]}]}}, {"name": "To evaluate the medico-economic impact of Eculizumab", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "_name": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "\u00c9valuer l'impact m\u00e9dico-\u00e9conomique de l'\u00e9culizumab"}]}]}}, {"name": "Objective of the first ancillary study: A first ancillary study will include a pangenomic analysis aimed at identifying new genetic variants associated with HE-aHUS. This ancillary study will be based on the residual genetic samples already scheduled in the biocollection. This ancillary study will be coordinated by Pr L. Mesnard (Nephrology Department, Tenon Hospital, Paris) and performed according to an already available funding", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "_name": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "Objectif de la premi\u00e8re \u00e9tude ancillaire :\nUne premi\u00e8re \u00e9tude ancillaire comprendra une analyse pang\u00e9nomique visant \u00e0 identifier de nouveaux variants g\u00e9n\u00e9tiques associ\u00e9s au HE-aHUS. Cette \u00e9tude ancillaire sera bas\u00e9e sur les \u00e9chantillons g\u00e9n\u00e9tiques r\u00e9siduels d\u00e9j\u00e0 pr\u00e9vus dans la biocollection. Cette \u00e9tude ancillaire sera coordonn\u00e9e par le Pr L. Mesnard (Service de N\u00e9phrologie, H\u00f4pital Tenon, Paris) et r\u00e9alis\u00e9e selon un financement d\u00e9j\u00e0 disponible."}]}]}}, {"name": "Objective of any other potential ancillary study: biological collection For any other ancillary study: residual samples will be stored for a biological collection to identify new potential genetic and pathophysiological determinants of HE-aHUS (Department of Immunobiology, HEGP, Dr Fr\u00e9meaux-Bacchi).", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "_name": {"extension": [{"url": "http://hl7.org/fhir/StructureDefinition/translation", "extension": [{"url": "lang", "valueCode": "fr"}, {"url": "content", "valueString": "Objectif de toute(s) autre(s) \u00e9tude(s) ancillaire(s) potentielle(s) : collection biologique \nIdentifier de nouveaux variants g\u00e9n\u00e9tiques li\u00e9s \u00e0 l'HE-aHUS.\nPour toute autre \u00e9tude ancillaire : les \u00e9chantillons r\u00e9siduels seront conserv\u00e9s pour une collection biologique afin d'identifier de nouveaux d\u00e9terminants g\u00e9n\u00e9tiques et physiopathologiques potentiels du HE-aHUS (D\u00e9partement d'Immunobiologie, HEGP, Dr Fr\u00e9meaux-Bacchi)."}]}]}}, {"name": "Primary Endpoints", "type": {"coding": [{"code": "primary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Primary"}]}, "outcomeMeasure": [{"name": "Response to therapy, defined by the absence of any of the following events: i) at 6-month follow-up: persistent renal replacement therapy, eGFR<15ml/mn/1,73m2, or patient death; ii) at W2 : persistent hemolysis despite well conducted antihypertensive therapy. Any Eculizumab rescue in the control group will be considered as a failure.", "type": {"coding": [{"code": "primary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Primary"}]}, "endpoint": {"type": "EvidenceVariable", "display": "CTIS2024-516402-32-00 Primary Outcome 1", "reference": "EvidenceVariable/346487", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "CTIS2024-516402-32-00 Primary Outcome 1", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}}]}, {"name": "Secondary Endpoints", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "outcomeMeasure": [{"name": "Prognosis role of repeat complement biomarkers (W1, W4, W13)", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "endpoint": {"type": "EvidenceVariable", "display": "CTIS2024-516402-32-00 Secondary Outcome 1", "reference": "EvidenceVariable/346488", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "CTIS2024-516402-32-00 Secondary Outcome 1", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}}, {"name": "Frequency of Complement genetic rare variants", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "endpoint": {"type": "EvidenceVariable", "display": "CTIS2024-516402-32-00 Secondary Outcome 2", "reference": "EvidenceVariable/346489", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "CTIS2024-516402-32-00 Secondary Outcome 2", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}}, {"name": "Renal replacement therapy rates at months 3 and 12 follow-up", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "endpoint": {"type": "EvidenceVariable", "display": "CTIS2024-516402-32-00 Secondary Outcome 3", "reference": "EvidenceVariable/346490", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "CTIS2024-516402-32-00 Secondary Outcome 3", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}}, {"name": "Frequency of severe infections (defined by the need for hospitalization)", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "endpoint": {"type": "EvidenceVariable", "display": "CTIS2024-516402-32-00 Secondary Outcome 4", "reference": "EvidenceVariable/346491", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "CTIS2024-516402-32-00 Secondary Outcome 4", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}}, {"name": "Time to resolution of haemolysis", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "endpoint": {"type": "EvidenceVariable", "display": "CTIS2024-516402-32-00 Secondary Outcome 5", "reference": "EvidenceVariable/346492", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "CTIS2024-516402-32-00 Secondary Outcome 5", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}}, {"name": "Time to resolution of renal replacement therapy", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "endpoint": {"type": "EvidenceVariable", "display": "CTIS2024-516402-32-00 Secondary Outcome 6", "reference": "EvidenceVariable/346493", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "CTIS2024-516402-32-00 Secondary Outcome 6", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}}, {"name": "Frequency and prognostic role of kidney lesions (glomerular and arteriolar microthromboses), glomerulosclerosis and kidney fibrosis if kidney biopsy is performed", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "endpoint": {"type": "EvidenceVariable", "display": "CTIS2024-516402-32-00 Secondary Outcome 7", "reference": "EvidenceVariable/346494", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "CTIS2024-516402-32-00 Secondary Outcome 7", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}}, {"name": "Costs relating to renal replacement therapy (or lack of), Eculizumab and other antihypertensive treatments, hospitalizations", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "endpoint": {"type": "EvidenceVariable", "display": "CTIS2024-516402-32-00 Secondary Outcome 8", "reference": "EvidenceVariable/346495", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "CTIS2024-516402-32-00 Secondary Outcome 8", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}}]}], "relatesTo": [{"type": "transforms", "targetUri": "https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-516402-32-00"}, {"type": "transformed-with", "targetAttachment": {"url": "https://fevir.net/ctisconvert", "title": "Computable Publishing\u00ae: CTIS-to-FEvIR Converter"}}], "classifier": [{"text": "Trial Category 2"}, {"text": "Justification for trial category assignment: Phase III"}, {"text": "Trial scope Therapy"}, {"text": "Trial scope Safety"}, {"text": "Trial scope Efficacy"}, {"coding": [{"code": "includes-females", "system": "https://fevir.net/resources/CodeSystem/419455", "display": "Includes female subjects"}]}, {"coding": [{"code": "includes-males", "system": "https://fevir.net/resources/CodeSystem/419455", "display": "Includes male subjects"}]}, {"coding": [{"code": "includes-vulnerable-population", "system": "https://fevir.net/resources/CodeSystem/419455", "display": "Includes vulnerable populations"}]}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"code": "ACSN", "system": "http://terminology.hl7.org/CodeSystem/v2-0203", "display": "Accession ID"}]}, "value": "346485", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}, {"use": "official", "value": "2024-516402-32-00", "system": "https://euclinicaltrials.eu/clinicalTrialId"}, {"use": "official", "value": "NCT05726916", "system": "https://clinicaltrials.gov"}], "recruitment": {"eligibility": {"type": "Group", "display": "CTIS2024-516402-32-00 Eligibility Criteria", "reference": "Group/346486", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "CTIS2024-516402-32-00 Eligibility Criteria", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}}, "resourceType": "ResearchStudy", "progressStatus": [{"state": {"coding": [{"code": "overall-study", "system": "http://terminology.hl7.org/CodeSystem/research-study-status", "display": "Overall study"}]}, "actual": false, "period": {"end": "2027-02-13"}}, {"state": {"coding": [{"code": "recruit", "system": "http://terminology.hl7.org/CodeSystem/research-study-status", "display": "Recruiting"}]}, "actual": false, "period": {"start": "2024-02-13"}}], "associatedParty": [{"name": "DGOS - French Ministry of Health", "role": {"coding": [{"code": "funding-source", "system": "http://terminology.hl7.org/CodeSystem/research-study-party-role", "display": "Funding source"}]}}, {"name": "Assistance Publique Hopitaux De Paris", "role": {"coding": [{"code": "sponsor", "system": "http://terminology.hl7.org/CodeSystem/research-study-party-role", "display": "Sponsor"}]}, "party": {"type": "Organization", "display": "Assistance Publique Hopitaux De Paris", "reference": "#organization-554686"}}, {"name": "Dr El Karoui Khalil", "role": {"text": "public contact", "coding": [{"code": "general-contact", "system": "http://terminology.hl7.org/CodeSystem/research-study-party-role", "display": "General contact"}]}, "party": {"type": "PractitionerRole", "display": "Dr El Karoui Khalil khalil.el-karoui@aphp.fr", "reference": "#contact-190857"}}, {"name": "Dr El Karoui Khalil", "role": {"text": "scientific contact", "coding": [{"code": "general-contact", "system": "http://terminology.hl7.org/CodeSystem/research-study-party-role", "display": "General contact"}]}, "party": {"type": "PractitionerRole", "display": "Dr El Karoui Khalil khalil.el-karoui@aphp.fr", "reference": "#contact-190858"}}]}